Request Demo

Last update 08 May 2025

PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

Last update 08 May 2025

Basic Info

Drugs associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

Carteolol Hydrochloride/Latanoprost

Target

PTGFR x β1-adrenergic receptor x β2-adrenergic receptor

Mechanism

PTGFR agonists [+2]

Active Org.

Otsuka Holdings Co., Ltd. [+2]

Originator Org.

Otsuka Pharmaceutical Co., Ltd.

Active Indication

Glaucoma [+2]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

Japan

First Approval Date28 Sep 2016

Clinical Trials associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

CTR20221401

/ Active, not recruitingPhase 3

一项评价OPC-1085EL 滴眼液治疗原发性开角型青光眼或高眼压症中国受试者的有效性及安全性的III期多中心、随机、单盲（评价者盲）、平行、阳性对照临床试验

[Translation] A Phase III multicenter, randomized, single-blind (evaluator-blind), parallel, positive-controlled clinical trial to evaluate the efficacy and safety of OPC-1085EL eye drops in the treatment of primary open-angle glaucoma or ocular hypertension in Chinese subjects

主要目的以原发性开角型青光眼或高眼压症中国受试者为对象，评价OPC-1085EL 滴眼液与0.005％拉坦前列素滴眼液相比的降眼压作用的优效性。次要目的比较OPC-1085EL滴眼液与0.005％拉坦前列素滴眼液使用的安全性。

[Translation]

Primary objective To evaluate the superiority of OPC-1085EL eye drops in lowering intraocular pressure compared with 0.005% latanoprost eye drops in Chinese subjects with primary open-angle glaucoma or ocular hypertension. Secondary objective To compare the safety of OPC-1085EL eye drops and 0.005% latanoprost eye drops.

Start Date27 Sep 2022

Sponsor / Collaborator

Teika Pharmaceutical Co., Ltd.

[+2]

NCT05583474

/ CompletedPhase 3

A Phase III, Multi-center, Randomized, Single-blind (to Evaluator), Parallel, and Positive-controlled Clinical Trial Evaluating the Efficacy and Safety of OPC-1085EL Ophthalmic Solution in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects

It is a phase III, multi-center, randomized, single-blind (to evaluator), parallel, and positive-controlled clinical trial evaluating the efficacy and safety of OPC-1085EL in the treatment of primary open angle glaucoma or ocular hypertension in Chinese subjects. It is planned that 240 subjects (120 in each group) will be randomly assigned to receive OPC-1085EL or 0.005% latanoprost ophthalmic solution (latanoprost) at a ratio of 1:1.

Start Date27 Sep 2022

Sponsor / Collaborator

Otsuka Beijing Research Institute

JPRN-UMIN000030288

/ CompletedNot ApplicableIIT

Investigation on the Efficacy and Safety of Carteolol/Latanoprost Combination Ophthalmic Solution to Timolol/Latanoprost Combination Ophthalmic Solution in Patients with Glaucoma - Investigation on the Efficacy and Safety of Carteolol/Latanoprost Combination Ophthalmic Solution in Patients with Glaucoma

Start Date22 Nov 2017

Sponsor / Collaborator-

100 Clinical Results associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

100 Translational Medicine associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

0 Patents (Medical) associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

Literatures (Medical) associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

01 Jun 1987·European Journal of PharmacologyQ3 · MEDICINE

Demonstration of the β2-adrenoceptor intrinsic efficacy of AY-28,925 using the PGF2α-contracted guinea-pig trachea

Q3 · MEDICINE

Article

Author: Heaslip, Richard J. ; Rimele, Thomas J. ; Giesa, Frank R. ; Grimes, David

The abilities of AY-28,925, labetalol and medroxalol to relax the PGF2 alpha-contracted isolated guinea-pig trachea have been investigated to compare their activities at beta 2-adrenoceptors. Maximum relaxation induced by AY-28,925 was significantly greater than that induced by either labetalol or medroxalol. This relaxation occurred in a concentration-dependent manner over a range of concentrations consistent with the previously determined affinity of AY-28,925 for beta-adrenoceptors. ICI-118,551 inhibited AY-28,925-induced relaxation in a concentration-dependent manner with a pA2 value similar to that determined for ICI-118,551 inhibition of the selective beta 2-adrenoceptor agonist salbutamol, but not the selective beta 1-adrenoceptor agonist norepinephrine. The Schild plot slope for ICI-118,551 inhibition of AY-28,925 or salbutamol did not differ significantly from unity, while that for inhibition of isoproterenol (a non-selective beta-adrenoceptor agonist) did. It is concluded that AY-28,925 is a more efficacious relaxant of tracheal smooth muscle than either labetalol or medroxalol, and that this relaxant activity is the result of its greater intrinsic efficacy at the beta 2-adrenoceptor.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

Basic Info

Related

Analysis